Secondary Leukaemia and Myelodysplasia after Autografting for Lymphoma: Is the Transplant to Blame?

References

• Carella A M., Pollicardo N, Pungolino Frassoni E. F., Giordano D, Bruni Spriano R. M., Rossi E. Autologous stem cell transplantation as adjuvent ??? vs no further therapy for poor risk Hodgkin's disease in first complete remission after MOPP/ABVD. Leukemia & Lymphoma 1995; 15(Suppl 1)59–61
   PubMed Web of Science ®Google Scholar
• Linch D C., Winfield D, Goldstone A H., Moir D, Hancock Mc B., Millan A, Chopra R, Milligan D W., Vaughan-Hudson G. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Yuen A, Rosenberg R. S, Hoppe A. RT., Halpern J D, Horning S J. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814–822
   PubMed Web of Science ®Google Scholar
• Phillip Guglielmi T., Hagenbeek C., Somers A., Van K., der Lelie Bron H., Sonneveld D., Gisselbrecht P. C., Cahn J Y, Harousseau J L., et al. New England Journal of Medicine 1995; 333(23)1540–5, Dec 7
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Gupta R K., Grenzelias D, Johnson P W., Pappa V I., Summers K, Salam E. A., Adams Norton A. A, Amess J. J, Matthews A. J., Bradburn M, Lister T A., Rohatiner A Z. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long term clinical and molecular follow-up. Journal ot Clinical Oncology 2000; 18: 527
   PubMed Web of Science ®Google Scholar
• Milpied N, Gaillard F, Moreau P, Mahe Soucbet B., Rapp J. M, Bulobois J. C, Morineau E. N., Harrousaeau J L. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors. a single centre experience. Bone Marrow Transplantation 1998; 22: 645–650
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Passweg J, Baldomero Hermans H. J. Blood and marrow transplantation activity in Europe in 1906. Bone Marrow Transplantation 1998; 22: 227–240
   PubMed Web of Science ®Google Scholar
• Bredeson Malcolm C. J., Davis M, Bence-Bruckler I, Kearns B, Huebsch L. Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow to peripheral blood progenitor cells Bone. Marrow Transplantation 1997; 20: 889–896
   PubMed Web of Science ®Google Scholar
• Glaspy J A. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplantation 1999; 23(Suppl 2)S21–27
   PubMed Web of Science ®Google Scholar
• Jagannath S, Vesole D H, Zhang M., Desikan J R, Copeland Jagannath N. M., Bracy D, Jones Crowley R., Tricot J. G., Barlogie B. Feasibility and cost-effectiveness of outpatient auto transplants in multiple myeloma. Bone Mallow Transplantation 1997; 20: 445–450
   PubMed Web of Science ®Google Scholar
• Meisenberg B, Ferran R. K., Hollenbach Brehm K. T., Jollon Piro J. LD. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplantation 1998; 21: 927–932
   PubMed Web of Science ®Google Scholar
• Zittoun Suciu K. S., Watson M, Soh G, Muus Mandelli P. F., Stryckmans Peetermans P. M., Thaler G, Resegotti L, Dardenne M, Willemze R. Quality of life in patients with acute myelogenous leukemia in prolonged complete first remission after bone marrow' transplantation (allogeneic or autologous) or chemotherapy. Bone Marrow Transplantation 1997; 20: 307–315
   PubMed Web of Science ®Google Scholar
• Neitzert C, Ritvo S., Dancey P., Weiser J. K., Murray C, Avery J. The psychosocial impact of bone marrow transplantation: a review ot the literature. Bone Marrow Transplantation 1998; 22: 409–422
   PubMed Web of Science ®Google Scholar
• Winer E P., Lindley Hardee C. M., Sawyer W, Brunatti P. C., Borstelman N A., Peters W. Quality of life in patients surviving at least twelve months following high dose chemotherapy with autologous bone marrow' support. Psyco-Oncology 1999; 8: 167–176
   PubMed Web of Science ®Google Scholar
• Marrolleau J, Brice P. P., Morel Gisselbrecht P. C. Secondary acure myeloid leukemia after hone marrow transplantation for malignant lymphomas (letter). Journal of Clinical Oncology 1993; 11: 590–591
   PubMed Web of Science ®Google Scholar
• Stone R M., Neuberg Soiffer D. R., Takvorian T, Whelan M, Rabinowe S, Aster N. J C, Leavitt Mauch P. P., Freedman A S, et al. Myelodysplastic syndrome as a late complication following autologous hone marrow transplantation for non-Hodgkin's lymphoma. Journal of Clinical Oncology 1994; 12: 2535
   PubMed Web of Science ®Google Scholar
• Miller J, Arthur S. D C, Litz C E., Neglia J P., Miller W J., Weisdorf J F. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83: 3780
   PubMed Web of Science ®Google Scholar
• Bhatia S, Ramsay N, Steinbuch K. M., Dusenbery K E, Shapiro R S, Weisdorf D J, Robinson L L, Miller J S, Neglia J P. Malignant neoplasms following bone marrow transplantation. Blood 1906; 87: 3633
   Google Scholar
• Darrington D, Vose L. J, Anderson M. J., Bierinan R. P J, Bishop M, Chan K. W C, Morris M, Reede E. E., Sanger C. W, Tarantolo G. S R, et al. Incidence and characterisation of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose transplantation-radiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Journal of Clinical Oncology 1994; 12: 2527
   PubMed Web of Science ®Google Scholar
• Amigo M L, del Canizo M, Rios C. A., Garcia M A., Caballero M, Martin D. A., Bermejo N, Vilches San P., Miguel J F. Diagnosis of secondary myelodysplastic syndromes following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplantation 1999; 23: 997–1002
   PubMed Web of Science ®Google Scholar
• Traweek S, Slovak I. M, Nadamenee C. A P, Brynes R, Niland K. J.C, Forman S J. Clonal karyotypic hemopoietic cell abnormalities occurring after autologous hone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 81: 957
   Google Scholar
• Sobecks R M., Le Beau M M, Anastasi J, Williams S F. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood transplantation. Bone Marrow transplantation 1999; 23: 1161–1165
   PubMed Web of Science ®Google Scholar
• Devereux S. Therapy associated leukaemia. Blood Rev 1991; 5: 138–145
   PubMed Web of Science ®Google Scholar
• Ambruzzese E, Radford J E., Miller J S., Vredenburgh J J., Rao P N., Pettenati M J., Cruz J M., Perry J J., Amadori S, Hurd D D. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 1999; 94: 1814–1819
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Larsen S O. Incidence of acute non lymphocytic leukemia, pre leukemia and acute myeloproliferative syndromes up to 10 years after treatment of Hodgkin's disease. New England Journal of Medicine 1982; 307: 965
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Specht L, Larsen S O, Ersboll J, Struck J, Hansen M M. Nissen NI Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Lancet 1987; 2: 83
   PubMed Web of Science ®Google Scholar
• Greene M H., Young R C., Merrill J M., De Vita V T. Evidence of a treatment dose response in acute nonlymphocytic leukaemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Research 1983; 43: 1891
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Ersboll J, Sorensen H M., Keiding M, Larsen S O, Philip P, Larsen M S., Schultz H, Nissen N I. Risk of acute non lymphocytic leukemia and pre leukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphoma. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Annals of Internal Medicine 1985; 103: 195
   PubMed Web of Science ®Google Scholar
• Kaldor J M., Day N E, Clarke A, Van Leeuwen F E., Henry-Amar Fiorentino M. M, et al. Leukemia following Hodgkin's disease. New England Journal of Medicine 1990; 322: 7
   PubMed Web of Science ®Google Scholar
• Swerdlow A J., Douglas A J., Vaughan-Hudson G, Vaughan-Hudson B, MacLennan K A. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationship to host factors, histology and stage of Hodgkin's disease, and splenectomy. British Journal of Cancer 1993; 68: 1006
   PubMed Web of Science ®Google Scholar
• Thirman M J, Larson R A. Therapy-related leukemia. Hematology and Oncology Clinics of North America 1996; 10: 293
   PubMed Web of Science ®Google Scholar
• Milligan D W., Ruiz de Elvira C M., Kolb H-J, Goldstone A H., Meloni G, Rohatiner A Z., Colombat P, Schmitz N. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. British Journal of Haematology 1999; 106: 1020–1026
   PubMed Web of Science ®Google Scholar
• Freedman A S., Neuberg D, Mauch P, Soiffer R J., Anderson K C., Fisher D C., Schlossman R, Alyea E P., Takvorian T, Jal-Low H., Kuhlman C, Ritz J, Nadler L M., Gribben J G. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333
   PubMed Web of Science ®Google Scholar
• Glicksman A S., Pajak T F., Gottlieb A, Nissen N, Stutzman L, Cooper M R. Second malignant neoplasms in patients successfully treated for Hodgkin's disease. Cancer Treatment Reports 1982; 66: 1035–1044
   PubMedGoogle Scholar
• Laughlin M J., McCaughey D S., Crews J R., Chao N J., Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, Le Grand S, Peters W P., Vrendburgh J J. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. Journal of Clinical Oncology 1998; 16: 1008–1012
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Jagannath S, Flick J T, Vesole D H, Sawyer J, Barlogie B, Tricot G. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Braematol J. H. 1996; 95: 349
   PubMed Web of Science ®Google Scholar
• André M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, et al. Treatment-related deaths and second cancer risks after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92: 1933
   PubMed Web of Science ®Google Scholar
• Krishnan A, Bhatia S, Slovak M, Arber D A, Niland J C, Nademanee A, Fung H, Bhatia R, Kashyap A, Molina A, O'Donnell M R., Parker P A, Sniecinski I, Snyder D S, Spielberger R, Stein A, Forman S J. Predictors of therapy related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593
   PubMed Web of Science ®Google Scholar
• Harrison C N., Gregory W, Vaughan-Hudson G, Devereux S, Goldstone A H., Hancock B, Winfield D, MacMillan A K., Hoskin P, Newland A C., Milligan D, Linch D C. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease in unlikely to be associated with a major increased risk of secondary MDS/AML. British Journal of Cancer 1999; 81: 476–483
   PubMed Web of Science ®Google Scholar
• Kumar L. Secondary leukaemia after autologous bone marrow transplantation. Lancet 1995; 345: 810
   PubMed Web of Science ®Google Scholar
• Roy D C, Tantravahi R, Murray C, Dear K, Gorgone Anderson B. KC, et al. Natural history of mixed chimerism after bone marrow transplantation with CD6 — depleted allogeneic marrow: a stable equilibrium. Blood 1990; 75: 296–304
   PubMed Web of Science ®Google Scholar
• Peniket A J, Taghipour G, Milligan D W, Blystad M, Goldstone A H. BEAM is a better conditioning regimen than cyclophosphamide/TBI for adults with lymphoblastic lymphoblastic undergoing autologous transplantation: a retrospective matched-pair analysis from the EBMT Registry. Bone Marrow Transplant 1997; 19: 573
   Google Scholar
• McQuaker I G, Haynes A P, Stainer C, Anderson S, Russell N H. Stem cell mobilisation in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. British Journal of Haematology 1997; 98: 228–233
   PubMed Web of Science ®Google Scholar